View Older Stories View More Recent Stories
-
Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
-
BioMarin Pharma (BMRN) Announces Positive Pivotal Data for PALYNZIQ in Adolescents with Phenylketonuria
-
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
How could tariffs shake up the pharma sector?
-
BioMarin Pharma (BMRN) Appoints Timothy P. Walbert to its Board
-
Oppenheimer Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
-
Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BMO Reiterates Outperform on BioMarin Pharmaceutical Inc. (BMRN) as 'Voxzogo Growth Continues'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at Piper Sandler; 'Strong Execution All Around'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $80 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $91 at Stifel
-
After-hours movers: Carvana, Klaviyo, NerdWallet, BioMarin Pharma, and more
-
BioMarin Pharma (BMRN) Tops Q4 EPS by 37c ; Offers Guidance
-
Goldman Sachs Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
-
BMO Capital Highlights Favorite Names for 2025 in Biotech
-
BioMarin Pharma (BMRN) 6K contracts of January 6K puts trade at 60c and 65c
-
Is Trump 2.0 good or bad for healthcare stocks?
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $65 at Baird
-
William Blair Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Market Perform
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $84 at Canaccord Genuity
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $105 at Leerink Partners
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $81 at Citi
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 38c; raises guidance
-
Raymond James Resumes BioMarin Pharmaceutical Inc. (BMRN) at Outperform
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $86 at Barclays
-
Increasing unusual put option volume: EVGO LEVI ASHR EQT BMRN FUTU
-
Goldman Sachs Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $78 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $90 at Truist Securities
-
Baird Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $85 at RBC Capital
-
BMO Capital Reiterates BioMarin (BMRN) at Outperform: unique opportunity to buy the dip and can attract M&A interest
-
Barclays Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Weakness Tied to Data From Ascendis Pharma (ASND)
-
Canaccord Genuity Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Increasing unusual call option volume: SMMT TERN SATS BNTX BRZE FRPT FLUT APLD TECS BMRN
-
BMO Capital Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $122 at Piper Sandler
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $118 at Truist Securities
-
BioMarin Pharma (BMRN) Provides New Corporate Strategy, Introduces 2027 Financial Guidance
-
BioMarin Pharma (BMRN) Enters $600M Revolving Credit Facility
-
BioMarin Pharma (BMRN) Halted, News Pending
-
BioMarin Pharma (BMRN) to reduce its global workforce by approximately 225 employees
-
Bernstein SocGen Group Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Goldman Sachs Shares 2 Idiosyncratic Trade Ideas off NVIDIA (NVDA) Earnings, Buy Calls on Dollar General (DG) and BioMarin Pharma (BMRN)

